Zhang Bei, Shanmugaraj Balamurugan, Daniell Henry
Department of Biochemistry, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA 19104-6030, USA.
Department of Biochemistry, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA 19104-6030, USA.
Curr Opin Chem Biol. 2017 Jun;38:17-23. doi: 10.1016/j.cbpa.2017.02.007. Epub 2017 Feb 23.
After approval of the first plant-made biopharmaceutical by FDA for human use, many protein drugs are now in clinical development. Within the last decade, significant advances have been made in expression of heterologous complex/large proteins in chloroplasts of edible plants using codon optimized human or viral genes. Furthermore, advances in quantification enable determination of in-planta drug dosage. Oral delivery of plastid-made biopharmaceuticals (PMB) is affordable because it eliminates prohibitively expensive fermentation, purification processes addressing major challenges of short shelf-life after cold storage. In this review, we discuss recent advances in PMBs against metabolic, inherited or infectious diseases, and also mechanisms of post-translational modifications (PTM) in order to increase our understanding of functional PMBs.
在美国食品药品监督管理局（FDA）批准首款植物源生物制药用于人体之后，目前许多蛋白质药物正处于临床开发阶段。在过去十年中，利用密码子优化的人类或病毒基因在可食用植物的叶绿体中表达异源复杂/大型蛋白质方面取得了重大进展。此外，定量分析方面的进展使得能够确定植物内药物剂量。口服递送叶绿体制造的生物制药（PMB）成本较低，因为它省去了极其昂贵的发酵和纯化过程，解决了冷藏后保质期短的主要挑战。在本综述中，我们讨论了PMB在治疗代谢性、遗传性或感染性疾病方面的最新进展，以及翻译后修饰（PTM）的机制，以增进我们对功能性PMB的理解。
